
Lars M König

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6390548/publications.pdf Version: 2024-02-01



LADS M KÃONIC

#	Article	IF	CITATIONS
1	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	22.5	80
2	Heterozygous <i>OAS1</i> gain-of-function variants cause an autoinflammatory immunodeficiency. Science Immunology, 2021, 6, .	11.9	36
3	Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19. Journal of Experimental Medicine, 2020, 217, .	8.5	35
4	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia, 2020, 34, 1017-1026.	7.2	33
5	Tousled-Like Kinases Suppress Innate Immune Signaling Triggered by Alternative Lengthening of Telomeres. Cell Reports, 2020, 32, 107983.	6.4	23
6	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. , 2019, 7, 288.		22
7	A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosis–Like Hyperinflammation. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3102-3111.	3.8	20
8	OAS1/RNase L executes RIG-I ligand–dependent tumor cell apoptosis. Science Immunology, 2021, 6, .	11.9	19
9	Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner. Frontiers in Immunology, 2021, 12, 595390.	4.8	16
10	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Scientific Reports, 2018, 8, 8810.	3.3	13
11	Metabolic implication of tigecycline as an efficacious secondâ€line treatment for sorafenibâ€resistant hepatocellular carcinoma. FASEB Journal, 2020, 34, 11860-11882.	0.5	13
12	Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy. Molecular Cancer Therapeutics, 2019, 18, 2343-2356.	4.1	12
13	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. Cancer Immunology, Immunotherapy, 2020, 69, 2101-2112.	4.2	12